Comparatively, treatment of cultured cystic cholangiocytes with the TGR5 antagonist, SBI-115, decreased proliferation, cholangiocyte spheroid growth and cAMP levels [84], suggesting that TGR5 inhibition may be a promising therapeutic approach to polycystic liver disease and treating malignant cholangiocytes. Here, GPBAR1 is linked to Isolated polycystic liver disease.